Hexasiil

Indications

• Prevention of diphtheria through vaccination
• Treatment of diphtheria infection
• Management of respiratory obstruction due to pseudomembrane

Dosage

Children: Refer to specific

Adults: Refer to specific guidelines for the treatment of diphtheria. Antitoxin and antibiotics are typically used in treatment.

Mechanism of action

The pathogenicity of Corynebacterium diphtheriae is largely due to its production of diphtheria toxin, an A-B toxin that inhibits protein synthesis in host cells. The toxin is composed of two subunits: the A subunit, which enters the cytoplasm of the cell and catalyzes the ADP-ribosylation of elongation factor 2 (EF-2), leading to cell death, and the B subunit, which binds to the cell surface receptor, facilitating the entry of the A subunit. This results in local tissue damage and systemic effects, including myocarditis and neuropathy.

Pharmacodynamics

Diphtheria toxin exerts its effects primarily through inhibiting protein synthesis, causing cell death in susceptible tissues. The resulting necrosis can lead to the characteristic pseudomembrane formation in the throat and can affect other organs, including the heart and nervous system. The immune response to the toxin and the bacteria provides some level of protection, which is the basis for vaccination strategies.

Pharmacokinetics

The pharmacokinetics of the diphtheria toxin itself are not typically described in terms of absorption, distribution, metabolism, and excretion, as it is a potent toxin rather than a conventional drug. However, the body’s immune response to the toxin is crucial for recovery. After vaccination, the body generates antibodies against the toxin, which can neutralize its effects upon exposure to the bacterium.

Pregnancy

Diphtheria vaccination is recommended during pregnancy to protect the mother and fetus. The vaccine is inactivated and poses no risk.

Breast-feeding

Diphtheria vaccination is safe during breastfeeding. Antibodies may be transferred to the infant through breast milk.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze.

Formulations

• Diphtheria toxoid vaccine

Indications

• Bacterial meningitis
• Pneumonia
• Epiglottitis
• Otitis media
• Sinusitis
• Bronchitis

Dosage

Children: Refer to specific antibiotic guidelines for pediatric dosing based on the type and severity of the infection caused by Haemophilus species.

Adults: Refer to specific antibiotic guidelines for dosing based on the type and severity of the infection caused by Haemophilus species.

Mechanism of action

H. influenzae adheres to epithelial cells via pili and other surface structures, allowing colonization of the nasopharynx. The encapsulated strains evade phagocytosis due to their polysaccharide capsule, which inhibits opsonization and complement activation. This leads to the systemic spread of the bacteria and can result in severe infections if not effectively treated.

Pharmacodynamics

H. influenzae can produce various virulence factors, including polysaccharide capsules, endotoxins, and enzymes that contribute to its pathogenicity. The bacteria can resist the effects of certain antibiotics through mechanisms such as beta-lactamase production, which hydrolyzes beta-lactam antibiotics, rendering them ineffective. The host's immune response is often inadequate to clear the infection due to the bacterium's ability to evade immune detection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat H. influenzae infections vary based on the specific drug. Common antibiotics include ampicillin and ceftriaxone. The absorption, distribution, metabolism, and excretion depend on the antibiotic used. For example, ampicillin is well absorbed from the gastrointestinal tract, widely distributed in body tissues and fluids, and eliminated primarily via renal excretion.

Adverse effects

• Injection site reactions
• Fever
• Rash
• Irritability
• Anaphylaxis (rare)

Precautions

• Caution in patients with a history of severe allergic reactions
• Monitor for signs of anaphylaxis after administration
• Assess for underlying immunocompromised conditions

Pregnancy

Safety during pregnancy has not been established; use only if clearly needed.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Injectable suspension
• Oral tablets

Indications

• Acute viral hepatitis
• Chronic hepatitis B
• Chronic hepatitis C
• Autoimmune hepatitis
• Alcoholic hepatitis
• Non-alcoholic fatty liver disease

Dosage

Children: Paediatric dosing also varies significantly based on the specific condition and medication. As with adult dosing, it is important to refer to the BNF for Children for specific recommendations.

Adults: Dosing for adult patients varies widely depending on the specific antiviral agent used and the type of hepatitis. It is essential to refer to specific guidelines or the BNF for precise dosing.

Mechanism of action

In viral hepatitis, the viruses typically enter liver cells and replicate, leading to cellular injury and inflammation. The immune response to the infection contributes to liver damage. Antiviral therapies aim to inhibit viral replication, either by directly targeting viral enzymes or by modulating the host immune response.

Pharmacodynamics

The pharmacodynamics of antiviral agents used in hepatitis treatment involve the inhibition of viral replication, reduction of viral load, and improvement of liver function. This can lead to a decrease in serum liver enzymes (ALT and AST) and an improvement in clinical symptoms. In chronic hepatitis B and C, sustained virologic response is the goal, indicating effective viral suppression.

Pharmacokinetics

The pharmacokinetics of antiviral medications used for hepatitis can vary significantly depending on the specific drug. Generally, these agents are absorbed from the gastrointestinal tract, metabolized in the liver, and excreted through urine or feces. The half-lives of these drugs can vary, influencing dosing schedules.

Pregnancy

Consult medical guidelines as hepatitis can pose risks during pregnancy; specific management depends on the type of hepatitis.

Breast-feeding

Consult healthcare providers, as the safety of certain hepatitis medications during breastfeeding varies.

Storage

Store in a cool, dry place away from direct sunlight; specific storage conditions may vary based on the medication used.

Indications

• Prevention of influenza virus infection in high-risk populations
• Annual vaccination as part of public health initiatives

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines.

Adults: Refer to the BNF for specific dosing guidelines.

Mechanism of action

The live influenza vaccine works by introducing attenuated strains of the influenza virus into the body. This stimulates the immune system to produce antibodies against the virus, providing immunity. The presence of these antibodies enables the body to recognize and respond more effectively to future infections with the actual influenza virus.

Pharmacodynamics

Upon administration, the live attenuated vaccine elicits a robust immune response characterized by the production of specific antibodies. These antibodies can neutralize the virus, reducing the likelihood of infection and associated complications. The vaccine not only promotes humoral immunity but also induces cellular immune responses, which contribute to long-lasting protection against influenza.

Pharmacokinetics

The live influenza vaccine is administered intranasally or intramuscularly. After administration, the vaccine components are taken up by the immune system, leading to the activation of immune cells. The onset of immunity typically occurs within two weeks, as the body develops a response to the antigens presented by the vaccine. It is important to note that the vaccine does not replicate in the host, and any remaining components are eventually cleared by the immune system.

Interactions

• normal immunoglobulin + influenza vaccine live: Unknown (decreases efficacy)

Indications

• Whooping cough (pertussis)
• Prevention of pertussis in infants and young children through vaccination

Dosage

Children: Refer to the BNF for Children for specific dosing information.

Adults: Refer to the BNF for specific dosing information.

Mechanism of action

Pertussis toxin, produced by Bordetella pertussis, acts on host cells by ADP-ribosylating a G protein, which disrupts normal signal transduction pathways. This leads to increased production of cyclic AMP, inhibiting immune responses and contributing to the characteristic symptoms of the disease.

Pharmacodynamics

The clinical manifestations of pertussis are largely due to the immune response to the toxin and the bacterium itself. The disease progresses through stages: the catarrhal stage with mild symptoms, the paroxysmal stage with intense coughing fits, and the convalescent stage where symptoms gradually improve. The severity can vary, particularly in infants and young children, who are at higher risk for complications.

Pharmacokinetics

The pharmacokinetics of Bordetella pertussis are not typically described in the same manner as pharmaceutical agents. The organism does not have a traditional pharmacokinetic profile, but it primarily colonizes the ciliated epithelial cells of the upper respiratory tract. The immune clearance of the bacteria can take several weeks, depending on the host's immune response and treatment.

Adverse effects

• Cough
• Vomiting
• Fatigue
• Apnea (especially in infants)
• Weight loss
• Paroxysms of coughing
• Encephalopathy (rare)
• Pneumonia (secondary infection)

Precautions

• Use with caution in individuals with a history of seizures
• Consider potential for severe respiratory distress, especially in infants
• Monitor for complications, particularly in young children

Pregnancy

Pertussis vaccination is recommended during pregnancy to protect the newborn, especially during outbreaks.

Breast-feeding

Vaccination during breastfeeding is safe and can provide passive immunity to the infant.

Storage

Store in a cool, dry place away from direct sunlight. Follow specific storage instructions for vaccines.

Formulations

• DTaP vaccine (Diphtheria, Tetanus, and Pertussis)
• Tdap vaccine (Tetanus, Diphtheria, and Pertussis)

Indications

• Prevention of poliomyelitis
• Vaccination in children and high-risk populations

Dosage

Children: Refer to the BNF for Children for appropriate dosing schedules and recommendations for poliovirus vaccination in children.

Adults: Refer to specific guidelines for IPV and OPV administration in adults, as vaccination schedules may vary based on age and immunization history.

Mechanism of action

Poliovirus primarily infects the motor neurons of the spinal cord and brainstem, leading to cell lysis and apoptosis. The viral replication occurs in the cytoplasm of the host cells, resulting in the release of new virions. The immune response triggered by the infection can lead to paralysis due to damage to the motor neurons.

Pharmacodynamics

The pharmacodynamics of polio vaccines involve the induction of an immune response against the poliovirus. The IPV induces serum neutralizing antibodies, while the OPV induces both serum and mucosal immunity. This immune response prevents the establishment of infection and protects against the disease.

Pharmacokinetics

Poliovirus vaccines do not have a pharmacokinetic profile in the traditional sense, as they are biological products. However, the IPV is administered intramuscularly, leading to systemic absorption and subsequent immunogenicity. The OPV is administered orally, leading to replication in the gastrointestinal tract and inducing both humoral and cellular immunity.

Contra-indications

• Severe allergic reaction to polio vaccine components
• Immunocompromised state (inactivated vaccine preferred)

Adverse effects

• Injection site reactions (pain, swelling, redness)
• Fever
• Fatigue
• Gastrointestinal disturbances (nausea, vomiting)
• Rarely, vaccine-derived paralytic poliomyelitis

Interactions

• Live vaccines may be affected by immunosuppressive therapies
• Concurrent administration with other vaccines is generally safe but consult vaccination guidelines

Precautions

• History of allergic reactions
• Patients with a history of Guillain-Barré syndrome
• Caution in patients with neurological disorders

Pregnancy

Polio vaccination is recommended during pregnancy if the woman is at risk of exposure, as the benefits outweigh potential risks.

Breast-feeding

Polio vaccine can be administered to breastfeeding mothers without risk to the infant.

Storage

Store at 2-8°C. Do not freeze. Protect from light.

Formulations

• Inactivated poliovirus vaccine (IPV)
• Oral poliovirus vaccine (OPV)

Indications

• Tetanus prophylaxis
• Treatment of tetanus infection
• Management of tetanus symptoms

Dosage

Children: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Adults: Refer to the specific guidelines for tetanus immunoglobulin and other supportive treatments as per clinical protocols.

Mechanism of action

The tetanus toxin binds to the presynaptic membrane of motor neurons and is transported retrogradely to the spinal cord, where it interferes with neurotransmitter release, particularly inhibiting the release of glycine and gamma-aminobutyric acid (GABA), leading to unopposed motor neuron activity and resultant muscle rigidity and spasms.

Pharmacodynamics

Tetanus toxin is one of the most potent toxins known, with effects that can manifest within hours of exposure. The toxin's ability to block inhibitory neurotransmitter release results in a state of continuous muscle contraction, known as tetany. The clinical presentation of tetanus includes trismus (lockjaw), muscle rigidity, and autonomic instability, among others.

Pharmacokinetics

The pharmacokinetics of tetanus toxin are complex due to its high potency and the nature of its action. Following entry into the body, the toxin binds to nerve endings and is internalized, leading to its effects on neurotransmitter release. The half-life of the toxin is not well defined as it does not circulate freely in the bloodstream but acts locally at the neuromuscular junction. Recovery from the effects of the toxin may take weeks to months, depending on the severity of the infection and the treatment provided.

Adverse effects

• Pain at the injection site
• Fever
• Fatigue
• Headache
• Nausea

Precautions

• Ensure patient is up to date with vaccinations
• Monitor for allergic reactions post-vaccination
• Consider history of neurological disorders

Pregnancy

Tetanus vaccination is considered safe during pregnancy and is recommended to protect both the mother and the newborn.

Breast-feeding

Tetanus vaccination is safe during breastfeeding and does not affect the nursing infant.

Storage

Store in a refrigerator at 2–8 degrees Celsius. Do not freeze.

Formulations

• Tetanus toxoid vaccine